Copyright
©The Author(s) 2019.
World J Gastroenterol. Oct 7, 2019; 25(37): 5687-5701
Published online Oct 7, 2019. doi: 10.3748/wjg.v25.i37.5687
Published online Oct 7, 2019. doi: 10.3748/wjg.v25.i37.5687
Table 5 Overall survival and recurrence-free survival
| Variable | Group | Total | P value | |
| Downstaging | Bridging | |||
| Overall survival (yr), (mean ± SD, range) | n = 20 | n = 87 | n = 107 | > 0.05 |
| 3.15 ± 1.33 (0.52-5.07) | 2.97 ± 1.66 (0-5.77) | 3.00 ± 1.60 (0-5.77) | ||
| Recurrence-free survival, (mean ± SD, range) | n = 20 | n = 86 | n = 106 | > 0.05 |
| 3.02 ± 1.37 (0.34-5.07) | 2.93 ± 1.69 (0-5.77) | 2.95 ± 1.63 (0-5.77) | ||
| Time of the waiting list until OLT (mo), (median, range) | n = 21 | n = 89 | n = 110 | < 0.051 |
| 10.6 (1.70-20.1) | 6.6 (0.60-30.47) | 7.0 (0.60-30.47) | ||
- Citation: Affonso BB, Galastri FL, da Motta Leal Filho JM, Nasser F, Falsarella PM, Cavalcante RN, de Almeida MD, Felga GEG, Valle LGM, Wolosker N. Long-term outcomes of hepatocellular carcinoma that underwent chemoembolization for bridging or downstaging. World J Gastroenterol 2019; 25(37): 5687-5701
- URL: https://www.wjgnet.com/1007-9327/full/v25/i37/5687.htm
- DOI: https://dx.doi.org/10.3748/wjg.v25.i37.5687